1381例原发性血小板增多症患者血栓风险因素的验证:一项多中心回顾性真实世界研究
该多中心回顾性真实世界研究在迄今最大规模的原发性血小板增多症(ET)患者队列(n=1381)中验证了r-IPSET-t评分,发现其较IPSET-t评分拟合更优。中位随访87.7个月,诊断后血栓事件发生率为0.578例/人年、出血事件为0.286例/人年。r-IPSET-t低危组与极低危组10年无血栓生存率分别为88%与99%(p<0.001)。
要点
- r-IPSET-t评分较IPSET-t对血栓的预测更优,低危组与极低危组10年无血栓生存率分别为88%与99%(p<0.001)。
- 诊断后抗血小板聚集治疗对血栓有保护作用(HR 0.31,p=0.005),但是大出血的危险因素(HR 10.56,p=0.021)。
- 真实世界中83.1%的极低危患者接受了阿司匹林,而ELN不推荐极低危患者使用阿司匹林。
核心结论
- r-IPSET-t评分对血栓的预测优于ELN推荐的IPSET-t评分,结果对不必要的降细胞治疗和抗血小板聚集治疗提出担忧。
研究设计与样本
- 多中心回顾性真实世界研究,纳入1381例原发性血小板增多症患者,验证r-IPSET-t评分。
- 平均随访87.7个月。
主要发现
- 诊断后血栓事件发生率为0.578例/人年,出血事件发生率为0.286例/人年。
- r-IPSET-t低危组与极低危组10年无血栓生存率分别为88%与99%(p<0.001)。
- 降细胞治疗在年轻患者(年龄<60岁)中是血栓危险因素(HR 9.49,p=0.026),在年龄≥60岁患者中HR 1.04(p=0.93)。
- 诊断后抗血小板聚集治疗对血栓有保护作用(HR 0.31,p=0.005),但是大出血的危险因素(HR 10.56,p=0.021)。
- IPSET-t高危组780例中132例被重新分类为低危组,低危组301例中249例被重新分类为极低危组(p<0.001)。
关键数值与推荐
- r-IPSET-t评分将患者分为极低危(VLR)、低危(LR)、中危(IR)和高危(HR)组。
- 欧洲白血病网(ELN)不推荐极低危患者使用阿司匹林。
- 本真实世界分析中83.1%的极低危患者接受了阿司匹林。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombosis and haemorrhage are frequent in patients with essential thrombocythaemia (ET). The 2016 revised International Prognostic Score for Thrombosis in Essential Thrombocythaemia-thrombosis (r-IPSET-t) score stratifies patients into very-low- (VLR), low- (LR), intermediate- (IR) and high-risk (HR) groups. We validated the r-IPSET-t in the biggest population of patients with ET (n = 1381) to date and found it to be a better fit than the earlier IPSET-t score. With an average follow-up of 87.7 months, there were 0.578 thrombotic events/person-year and 0.286 bleeding events/person-year after diagnosis. The 10-year thrombosis-free survival was 88% and 99% for the r-IPSET-t LR and VLR groups (p < 0.001). Cytoreduction was a thrombotic risk factor in younger patients (aged <60 years, hazard ratio 9.49, p = 0.026; aged ≥60 years, hazard ratio 1.04, p = 0.93). In multivariable Cox regression analysis, anti-aggregation after diagnosis was protective for thrombosis (hazard ratio 0.31, p = 0.005) but a risk factor for major bleeding (hazard ratio 10.56, p = 0.021). Of the IPSET-t HR and LR groups, 132/780 and 249/301 were re-classified as LR and VLR respectively (p < 0.001). The European LeukemiaNET (ELN) does not recommend aspirin for VLR patients but in this real-life analysis 83.1% of VLR patients received it. Our results validate the r-IPSET-t score as more predictive for thrombosis than the ELN-recommended IPSET-t and raise concerns about unnecessary cytoreductive and anti-aggregative therapy.
引用
- Stuckey R, Ianotto JC, Santoro M, et al. Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: A multicentre retrospective real-life study. Br J Haematol. 2022. PMID: 35906782. doi:10.1111/bjh.18387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。